OCT 11, 2018 12:00 PM PDT

Lung Cancer Evolution and Immune Escape

Speaker
  • Senior Research Associate, Cancer Genome Evolution Research Group, University College London
    Biography
      Dr. Nicholas McGranahan completed his undergraduate degree in Natural Sciences, specializing in Evolutionary Genetics, at the University of Bath before pursuing post-graduate studies at University College London at the Centre of Mathematics and Physics in the Life Science and Experimental Biology (CoMPLEX). In 2011, Dr. McGranahan joined Professor Charles Swanton's group at the CR-UK London Research Institute (now the Francis Crick Institute), completing a PhD in Cancer Genomics in 2015.

      As a junior group leader and Sir Henry Dale Fellow within the CRUK Lung Cancer Centre of Excellence, Dr. McGranahan's research interests include using bioinformatics to dissect cancer genome evolution and the mechanisms of drug resistance, intra-tumour heterogeneity and genomic instability. His work involves exploring the evolutionary history of cancers through sequencing multiple regions of individual tumours. In particular, Dr. McGranahan's research has focused on understanding the importance of genome doubling in tumour evolution, as well as exploring the mutational processes shaping the genomes of cancers over space and time. Dr McGranahan has authored over 30 articles in high impact journals, including first author publications in New England Journal of Medicine, Science, Nature and Cell.

    Abstract

    Lung cancer is the leading cause of cancer-related mortality worldwide. Large-scale sequencing studies have revealed the complex genomic landscape of NSCLC and genomic differences between lung adenocarcinomas (LUAD) and lung squamous cell carcinomas (LUSC). However, in-depth exploration of NSCLC intratumor heterogeneity and cancer genome evolution has been limited to small retrospective cohorts. As such, the clinical significance of ITH and the potential for clonality of driver events to guide therapeutic strategies is not yet defined.

    In this talk I will outline how intra-tumor heterogeneity can be deciphered using multi-region sequencing. I will examine how heterogeneity can be utilized to gain a deeper understanding of tumor evolution, focusing on results from the TRACERx  (TRAcking non-small cell lung Cancer Evolution through therapy (Rx)) study.

    I will explore the clinical implications of intra-tumor heterogeneity and consider clinical approaches to tackle this devastating disease. 

    Learning Objectives: 

    1. Tumour heterogeneity is widespread in early stage NSCLC and occurs at both mutational and copy number level
    2. APOBEC-mediate mutagenesis occurs later in lung cancer evolution and is associated with subclonal expansions
    3. HLA LOH is a pervasive mechanisms of immune evasion. 


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    APR 01, 2021 8:00 AM PDT
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    MAR 16, 2021 10:00 AM PDT
    C.E. CREDITS
    MAR 16, 2021 10:00 AM PDT
    Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
    OCT 11, 2018 12:00 PM PDT

    Lung Cancer Evolution and Immune Escape


    Specialty

    Cancer

    Cancer Research

    Cancer Diagnostics

    Oncology

    Pcr/rt-Pcr/real-Time Pcr

    Bioinformatics

    Research And Development

    Gene Expression

    Molecular Biology

    Lab Safety

    Human Behavior

    Tumor

    Molecular Diagnostics

    Human Genetics

    Flow Cytometry

    Geography

    North America50%

    Asia30%

    Europe20%

    Registration Source

    Website Visitors100%

    Job Title

    Student22%

    Research Scientist22%

    Medical Laboratory Technician22%

    Pharmacist11%

    Clinical Laboratory Scientist11%

    Executive11%

    Organization

    Hospital20%

    Academic Institution10%

    Manufacturer - Other10%

    Clinical Laboratory10%

    Biotech Company10%

    Contract Research Organization (Cro)10%

    Government10%

    Other20%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more